Increased Galectin-9 Concentration and Number of CD4+Foxp3high+Cells in Bronchoalveolar Lavage Fluid of Patients with Cryptogenic Organizing Pneumonia

Overview

Journal Lung

Specialty Pulmonary Medicine

Date 2015 Aug 8

PMID 26249221

Citations 4

Authors

Shigeki Katoh

Masaki Ikeda

Hiroki Shimizu

Masaaki Abe

Yoshihiro Ohue

Keiji Mouri

Yoshihiro Kobashi

Mikio Oka

Affiliations

Soon will be listed here.

Abstract

Purpose: Galectin-9 (Gal-9) is a β-galactoside-binding protein that exhibits various biological reactions, such as chemoattraction, cell aggregation, and apoptosis. Recent studies demonstrated that Gal-9 has a role as an immunomodulator in excessive immunological reactions by expanded regulatory T cells (Tregs). We examined the role of Gal-9 in the pathogenesis of one of the major idiopathic interstitial pneumonias, cryptogenic organizing pneumonia (COP) as compared with idiopathic pulmonary fibrosis (IPF).

Methods: Gal-9, transforming growth factor-β1, and interleukin (IL)-10 levels in the bronchoalveolar lavage fluid (BALF) of patients with COP and IPF were estimated by enzyme-linked immunosorbent assay. Forkhead box protein 3 (Foxp3) expressing Tregs were evaluated by flow cytometry. The effect of Gal-9 on interactions between human lung fibroblast cells and hyarulonan was assessed in vitro.

Results: Gal-9 and IL-10 levels in the BALF were significantly higher in patients with COP than in patients with IPF. The number of CD4+Foxp3high+cells was significantly higher in the BALF of patients with COP than in those with IPF. Gal-9 levels significantly correlated with the absolute number of CD4+CD25+Foxp3+cells or CD4+Foxp3high+cells, but not with the absolute number of CD4+CD25+Foxp3-cells, in the BALF of patients with COP. Gal-9 suppressed the CD44-dependent interaction of human lung fibroblast cells with hyarulonan in a dose-dependent manner.

Conclusions: Our findings suggest that increased Gal-9 levels in the lung have a protective role against lung inflammation and fibrosis in patients with COP through the induction of Tregs in the lung and CD44-dependent inhibitory effects on lung fibroblast cells.

Citing Articles

Update on cryptogenic organizing pneumonia.

Radzikowska E, Fijolek J Front Med (Lausanne). 2023; 10:1146782.

PMID: 37153105 PMC: 10157489. DOI: 10.3389/fmed.2023.1146782.

Circulating Levels of PD-L1, TIM-3 and MMP-7 Are Promising Biomarkers to Differentiate COVID-19 Patients That Require Invasive Mechanical Ventilation.

Chavez-Galan L, Ruiz A, Martinez-Espinosa K, Aguilar-Duran H, Torres M, Falfan-Valencia R Biomolecules. 2022; 12(3).

PMID: 35327637 PMC: 8946215. DOI: 10.3390/biom12030445.

Aberrantly Expressed Galectin-9 Is Involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease.

Liang L, Zhang Y, Shen Y, Song A, Li W, Ye L Front Cell Dev Biol. 2021; 9:628128.

PMID: 33842457 PMC: 8027128. DOI: 10.3389/fcell.2021.628128.

Hashimoto's thyroiditis-induced cryptogenic organizing pneumonia: A case report.

Guo L, Chen B, Zhang L, Deng Y, Li H, Shi Q Exp Ther Med. 2019; 18(6):4609-4616.

PMID: 31807148 PMC: 6878873. DOI: 10.3892/etm.2019.8143.

References

Matsumoto N, Katoh S, Yanagi S, Arimura Y, Tokojima M, Ueno M . A possible role of galectin-9 in the pulmonary fibrosis of patients with interstitial pneumonia. Lung. 2013; 191(2):191-8. DOI: 10.1007/s00408-012-9446-0. View

DAlessio F, Tsushima K, Aggarwal N, West E, Willett M, Britos M . CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Clin Invest. 2009; 119(10):2898-913. PMC: 2752062. DOI: 10.1172/JCI36498. View

Katoh S, Ishii N, Nobumoto A, Takeshita K, Dai S, Shinonaga R . Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am J Respir Crit Care Med. 2007; 176(1):27-35. DOI: 10.1164/rccm.200608-1243OC. View

Idali F, Wahlstrom J, Muller-Suur C, Eklund A, Grunewald J . Analysis of regulatory T cell associated forkhead box P3 expression in the lungs of patients with sarcoidosis. Clin Exp Immunol. 2008; 152(1):127-37. PMC: 2384071. DOI: 10.1111/j.1365-2249.2008.03609.x. View

Paust S, Cantor H . Regulatory T cells and autoimmune disease. Immunol Rev. 2005; 204:195-207. DOI: 10.1111/j.0105-2896.2005.00247.x. View

Katoh S, Oomizu S, Niki T, Shimizu H, Obase Y, Korenaga M . Possible regulatory role of galectin-9 on Ascaris suum-induced eosinophilic lung inflammation in mice. Int Arch Allergy Immunol. 2012; 158 Suppl 1:58-65. DOI: 10.1159/000337769. View

Hou J, Sun Y, Hao Y, Zhuo J, Liu X, Bai P . Imbalance between subpopulations of regulatory T cells in COPD. Thorax. 2013; 68(12):1131-9. DOI: 10.1136/thoraxjnl-2012-201956. View

Sakaguchi S . Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005; 6(4):345-52. DOI: 10.1038/ni1178. View

Wu C, Thalhamer T, Franca R, Xiao S, Wang C, Hotta C . Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity. 2014; 41(2):270-82. PMC: 4219323. DOI: 10.1016/j.immuni.2014.06.011. View

10.

Katoh S, Ikeda M, Shimizu H, Mouri K, Obase Y, Kobashi Y . Increased levels of plasma galectin-9 in patients with influenza virus infection. Tohoku J Exp Med. 2014; 232(4):263-7. DOI: 10.1620/tjem.232.263. View

11.

Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A . Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009; 30(6):899-911. DOI: 10.1016/j.immuni.2009.03.019. View

12.

OGarra A, Vieira P . Regulatory T cells and mechanisms of immune system control. Nat Med. 2004; 10(8):801-5. DOI: 10.1038/nm0804-801. View

13.

Hirashima M, Kashio Y, Nishi N, Yamauchi A, Imaizumi T, Kageshita T . Galectin-9 in physiological and pathological conditions. Glycoconj J. 2004; 19(7-9):593-600. DOI: 10.1023/B:GLYC.0000014090.63206.2f. View

14.

Takahashi K, Eto H, Tanabe K . Involvement of CD44 in matrix metalloproteinase-2 regulation in human melanoma cells. Int J Cancer. 1999; 80(3):387-95. DOI: 10.1002/(sici)1097-0215(19990129)80:3<387::aid-ijc9>3.0.co;2-t. View

15.

Raghu G, Collard H, Egan J, Martinez F, Behr J, Brown K . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6):788-824. PMC: 5450933. DOI: 10.1164/rccm.2009-040GL. View

16.

Li Y, Jiang D, Liang J, Meltzer E, Gray A, Miura R . Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med. 2011; 208(7):1459-71. PMC: 3135364. DOI: 10.1084/jem.20102510. View

17.

Zhu C, Anderson A, Schubart A, Xiong H, Imitola J, Khoury S . The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005; 6(12):1245-52. DOI: 10.1038/ni1271. View

18.

Katoh S, Nobumoto A, Matsumoto N, Matsumoto K, Ehara N, Niki T . Involvement of galectin-9 in lung eosinophilia in patients with eosinophilic pneumonia. Int Arch Allergy Immunol. 2010; 153(3):294-302. DOI: 10.1159/000314371. View

19.

Travis W, Costabel U, Hansell D, King Jr T, Lynch D, Nicholson A . An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188(6):733-48. PMC: 5803655. DOI: 10.1164/rccm.201308-1483ST. View

20.

Arikawa T, Saita N, Oomizu S, Ueno M, Matsukawa A, Katoh S . Galectin-9 expands immunosuppressive macrophages to ameliorate T-cell-mediated lung inflammation. Eur J Immunol. 2009; 40(2):548-58. DOI: 10.1002/eji.200939886. View